Bringing new products to market is particularly challenging for companies in the life sciences sector. It can be a long and risk-filled pathway from the lab to the shelf, often requiring careful navigation through rigorous testing and regulatory compliance. To be viable and competitive, a company’s business plan must include a comprehensive and proactive intellectual property strategy—investors expect it and the marketplace demands it.
As IP attorneys and professionals working with innovators dedicated to creating life-saving and life-improving products, we see first-hand how deliberate and holistic IP asset protection makes the difference, particularly when it comes to enforcing rights to keep competitors at bay or defending against infringement allegations. We apply our science and engineering backgrounds and full scope IP-focused legal acumen, drawn from real life experience in litigation, prosecution, and counseling, to keep clients in business so they can keep making and collaborating on groundbreaking scientific discoveries and inspired technological applications.
Finnegan advises clients on virtually every intellectual property issue, whether it is related to patents, trademarks, copyrights, or trade secrets. Our practice comprises experienced attorneys and professionals who have an in-depth understanding of the complex legal, technical, regulatory, and business issues faced by industries innovating in the life sciences.
We help with:
Our Life Sciences practice includes attorneys and professionals with degrees in relevant scientific disciplines such as biology, chemistry, biochemistry, medicine, pharmacology, biomedical engineering, or electrical engineering, as well as attorneys with extensive experience in brand management and protection. Many joined Finnegan after holding positions in industry, at universities, or as examiners with the U.S. Patent and Trademark Office.
Introduced nearly ten years ago, the Biologics Price Competition and Innovation Act (BPCIA) opened the door for companies to seek U.S. Food and Drug Administration (FDA) approval to manufacture and sell biosimilar or interchangeable versions of brand name biological products.
Finnegan works with biotech pioneers to develop and execute successful intellectual property strategies, including patenting ground-breaking advancements, enforcing patents in litigation, and defending against claims of infringement or ownership by others.
Success in Abbreviated New Drug Application (ANDA) litigation in the U.S. often begins months or even years before a case is filed. Whether you are anticipating receipt of a Paragraph IV notice letter or still in late-stage clinical trials, it is never too early to start preparation.
Consumers have access to an ever-growing number of affordable and portable devices designed to provide metrics and details about personal health and lifestyle. In an increasingly connected world, this type of information can be invaluable in helping healthcare professionals provide higher levels of care.
Finnegan has the legal experience and technical expertise to help clients address the many issues that arise in developing, protecting, and commercializing medical device and diagnostic inventions.
Even with billions of dollars invested in research and development, few drugs make it through clinical trials and stringent regulatory clearances necessary to get to market. For those that do, it is crucial that the companies have protected the intellectual property (IP) underlying new drugs and treatments.
In a rare rehearing proceeding, successfully represented petitioner Incyte in an inter partes review (IPR) challenging the validity of Concert’s patent before the Patent Trial and Appeal Board (PTAB). Continued representation of appellee Incyte before the Federal Circuit and secured a unanimous affirmance of the PTAB’s obviousness determination.
IPR2017-01256, PTAB, Judges Fitzpatrick, Hulse, Yang, Smith, Franklin
19-2011, Fed. Cir., Judges Hughs, Linn, Stark
1:23-cv-00756, D. Del., Judge Williams
2:23-cv-00094, 2:23-cv-02364, D.N.J., Judges Cecchi, Padin, Wettre
1:21-cv-01610, D. Del., Judges Andrews, Hall
IPR2022-01200, PGR2022-00051, PTAB, Judges Newman, Snedden, Wisz
22-2232, Fed. Cir.
Represented Intuitive Surgical Operations on appeals from petitions for inter partes review (IPR) filed by Auris Health, Inc.
21-1473, -1732, -1733, Fed. Cir., Judges Prost, Dyk, Reyna
IPR2019-01173, -01533, -01547, PTAB, Judges Franklin, Hulse, Jenks, Worth, Yang
Conference
2nd Annual Forum on IP, Funding and Tech Strategies for Novel Therapeutic Modalities
March 20, 2024
Boston
Ad Law Buzz Blog
“Banning” a Banned Ingredients Claim: NAD’s Application (and Expansion) of the FTC’s Green Guides
March 18, 2024
Articles
How to Avoid Common Pitfalls and Protect IP in Today’s Life Sciences Industry Joint Ventures
February 29, 2024
Webinar
February 15, 2024
Webinar
Workshop
Life Sciences Workshop: Updates and Key Trends in Pharmaceutical and Biotechnology IP Law
May 2, 2024
Cambridge
Apple Eyes Long-Term Software Fix for Watch While Appealing Ban
December 28, 2023
Award/Ranking
Asian Legal Business Names Finnegan “International IP Law Firm of the Year”
November 10, 2023
Award/Ranking
Five Finnegan Partners Named 2024 Leading Litigators in America by Lawdragon
October 30, 2023
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.